CRVS

Over the past six months, Corvus Pharmaceuticals' stock price has been impacted by several events. In November 2025, the company provided a business update and reported Q3 2025 financial results. January 2026 saw a significant surge in the company's shares after the announcement of positive Phase 1 trial data for soquelitinib in atopic dermatitis, followed by an upsized underwritten public offering. In February 2026, Corvus Pharmaceuticals presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. March 2026 included a business update and the reporting of fourth quarter and full-year 2025 financial results. In April 2026, the company announced the appointment of Andrew C. Chan, M.D., Ph.D., to its Board of Directors and plans to host an investor and analyst meeting in May 2026 to highlight soquelitinib data. On May 7, 2026, Corvus Pharmaceuticals provided a business update and reported its first-quarter 2026 financial results, noting key clinical advances for soquelitinib and a cash runway into Q2 2028. While the stock's price has increased significantly over the last 12 months, it experienced a decrease in the past month.